<DOC>
	<DOCNO>NCT00093015</DOCNO>
	<brief_summary>The purpose study assess impact treatment anemia darbepoetin alfa hemoglobin target 13 g/dL ( 1 ) all-cause mortality nonfatal cardiovascular event , ( 2 ) progression end-stage renal disease death , subject chronic kidney disease type 2 diabetes mellitus . Academic PI/Executive Committee Chairman : Marc Pfeffer , MD , PhD</brief_summary>
	<brief_title>Trial Reduce Cardiovascular Events With AranespÂ® Therapy ( TREAT )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Hemoglobin le equal 11 g/dL History Chronic Kidney Disease eGFR ( estimate glomerular filtration rate ) great equal 20 mL/min/1.73 m2 less equal 60 mL/min/1.73 m2 Tsat ( transferrin saturation ) great 15 % Uncontrolled hypertension Erythropoietic protein use within 12 week randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>